Research Publications

An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction.

Shen GQ, Li L, Girelli D, Seidelmann SB, Rao S, Fan C, Park JE, Xi Q, Li J, Hu Y, Olivieri O, Marchant K, Barnard J, Corrocher R, Elston R, Cassano J, Henderson S, Hazen SL, Plow EF, Topol EJ, Wang QK

Thrombospondins, their polymorphisms, and cardiovascular disease.

Stenina OI, Topol EJ, Plow EF

A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease.

Luke MM, Kane JP, Liu DM, Rowland CM, Shiffman D, Cassano J, Catanese JJ, Pullinger CR, Leong DU, Arellano AR, Tong CH, Movsesyan I, Naya-Vigne J, Noordhof C, Feric NT, Malloy MJ, Topol EJ, Koschinsky ML, Devlin JJ, Ellis SG

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.

Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH, Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ, CHARISMA Investigators

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.

Saw J, Brennan DM, Steinhubl SR, Bhatt DL, Mak KH, Fox K, Topol EJ, CHARISMA Investigators

Impact of sex, metabolic syndrome, and diabetes mellitus on cardiovascular events.

Mak KH, Ma S, Heng D, Tan CE, Tai ES, Topol EJ, Chew SK

The genomics gold rush.

Topol EJ, Murray SS, Frazer KA

Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.

Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A, Steinhubl S, Tan WA, Resar JR, AlMahameed A, Abdel-Latif A, Tang WH, Brennan D, McErlean E, Hazen SL, Topol EJ

Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial.

Brener SJ, Steinhubl SR, Berger PB, Brennan DM, Topol EJ, CREDO Investigators

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.

Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA, CHARISMA Investigators